No. | Tumor site | Number of patients | Treatment used | Results | Reference |
1 | Relapsed high-grade gliomas | 15 | mEHT + alkylating chemotherapy | Tolerable and safe for patients with relapses by high escalation of the dose too. | Wismeth, et al. 2010 [144] |
2 | Advanced gliomas | 12 | Chemotherapy, radiotherapy + mEHT | CR = 1, PR = 2, RR = 25%. Median duration of response = 10 m. Median survival = 9 m, 25% survival rate at 1 year. | Fiorentini, Giovanis, et al. 2006 [145] |
3 | Relapsed malignant gliomas | 24 | mEHT | Median survival = 19.5 months, 55% survival rate at 1 year, 15% at 2 years. | Fiorentini, Sarti, et al. 2018 [146] |
4 | Advanced glioblastoma | 60 | mEHT + immunotherapy | No added toxicity by immunotherapy. Median progression-free survival (PFS) = 13 m. Median follow up 17 m, median OS was not reached. Estimated OS at 30 m was 58%. | Van Gool, et al. 2018 [142] |
5 | Various brain-gliomas | 140 | Chemotherapy + radiotherapy + mEHT | OS = 20.4 m. mEHT was safe and well tolerated. | Sahinbas, et al. 2007 [147] |
6 | High-grade gliomas | 179 | mEHT + radiotherapy + chemotherapy | Longstanding complete and partial remissions after recurrence in both groups. | Hager, Groenemeyer, et al. 2008 [148] |